JB Pharma Q1 Profit, Margin Climb

  Published 8 months ago

JB Pharma's Q1 FY26 PBT rose 13.25% YoY to Rs 271.61 crore, with the operating EBITDA margin crossing the 30% milestone.

  • Operating EBITDA grew 13% YoY to Rs 330 crore, with margin rising to 30.2% from 29% last year.
  • Domestic business saw 14% value growth, led by acute, chronic, and ophthalmology segment performance.
  • CDMO segment remains strong, with JB Pharma focused on topline growth, cost control, and sustained profitability.

You might like these

Coforge Q1 Revenue Up, Stock Falls

Lula Slams Trump's Tariff Threats, Vows Reciprocity Rights

Embassy Develops Premium Bangalore Project

Ola Electric Plans Major Fundraise

Oracle Partners with AI Innovators to Boost Cloud AI

Nestlé Q3 Growth, Jobs Cuts, New CEO

NBCC's Zoo Project Contract Summary

News that matters the most ⚡